Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 305, Issue 17, Pages 1777-1785Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2011.574
Keywords
-
Categories
Funding
- European Union [IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093]
- Studies Coordinating Centre (Leuven, Belgium) [HEALTH-F4-2007-201550]
- studies in Pilsen (Czech Republic)
- studies in Pilsen, Padova (Italy)
- studies in Pilsen, Krakow (Poland)
- Novosibirsk (Russian Federation)
- Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium [G.0575.06, G.0734.09]
- Katholieke Universiteit Leuven, Belgium [OT/00/25, OT/05/49]
- Polish Ministry for Science and Higher Education
- Czech Society of Hypertension
Ask authors/readers for more resources
Context Extrapolations from observational studies and short-term intervention trials suggest that population-wide moderation of salt intake might reduce cardiovascular events. Objective To assess whether 24-hour urinary sodium excretion predicts blood pressure (BP) and health outcomes. Design, Setting, and Participants Prospective population study, involving 3681 participants without cardiovascular disease (CVD) who are members of families that were randomly enrolled in the Flemish Study on Genes, Environment, and Health Outcomes (1985-2004) or in the European Project on Genes in Hypertension (1999-2001). Of 3681 participants without CVD, 2096 were normotensive at baseline and 1499 had BP and sodium excretion measured at baseline and last follow-up (2005-2008). Main Outcome Measures Incidence of mortality and morbidity and association between changes in BP and sodium excretion. Multivariable-adjusted hazard ratios (HRs) express the risk in tertiles of sodium excretion relative to average risk in the whole study population. Results Among 3681 participants followed up for a median 7.9 years, CVD deaths decreased across increasing tertiles of 24-hour sodium excretion, from 50 deaths in the low (mean, 107 mmol), 24 in the medium (mean, 168 mmol), and 10 in the high excretion group (mean, 260 mmol; P<.001), resulting in respective death rates of 4.1% (95% confidence interval [CI], 3.5%-4.7%), 1.9% (95% CI, 1.5%-2.3%), and 0.8% (95% CI, 0.5%-1.1%). In multivariable-adjusted analyses, this inverse association retained significance (P=.02): the HR in the low tertile was 1.56 (95% CI, 1.02-2.36; P=.04). Baseline sodium excretion predicted neither total mortality (P=.10) nor fatal combined with nonfatal CVD events (P=.55). Among 2096 participants followed up for 6.5 years, the risk of hypertension did not increase across increasing tertiles (P=.93). Incident hypertension was 187 (27.0%; HR, 1.00; 95% CI, 0.87-1.16) in the low, 190 (26.6%; HR, 1.02; 95% CI, 0.89-1.16) in the medium, and 175 (25.4%; HR, 0.98; 95% CI, 0.86-1.12) in the high sodium excretion group. In 1499 participants followed up for 6.1 years, systolic blood pressure increased by 0.37 mm Hg per year (P<.001), whereas sodium excretion did not change (-0.45 mmol per year, P=.15). However, in multivariable-adjusted analyses, a 100-mmol increase in sodium excretion was associated with 1.71 mm Hg increase in systolic blood pressure (P.<001) but no change in diastolic BP. Conclusions In this population-based cohort, systolic blood pressure, but not diastolic pressure, changes over time aligned with change in sodium excretion, but this association did not translate into a higher risk of hypertension or CVD complications. Lower sodium excretion was associated with higher CVD mortality. JAMA. 2011;305(17):1777-1785 www.jama.com
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available